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Abstract 
A biomarker is a measurable indicator of the severity or presence of some disease. A biomarker is 
anything that can be used as an indicator of a particular disease state or some other physiological 
state of an organism. The space Decomposition-Gradient-Regression (DGR) method has been 
developed (Li et al., 2012; Li et al., 2015) to select biomarkers for schizophrenia. This study performs 
the DGR approach on data for bipolar disorder patients, which contains 56 biomarkers and 8 
infectious agent’s antibodies. Serum specimens were collected from 132 United States military service 
members (118 males and 14 females) with a diagnosis of bipolar disorder from 1992 to 2005 and their 
matched healthy controls.. Trefoil Factor3 (TFF3), Gliadin, prolactin (PRL), Apolipoprotein A-II (Apo 
A-II) and Immunoglobulin A (IGA) were found to be significant predictors of Bipolar Disorder (BD) in 
males. Macrophage-Derived Chemokine (MDC), Alpha-1-Antitrypsin (AAT), Gliadin, 
Beta-2-Microglobulin (B2M) and Monocyte Chemotactic Protein 2 (MCP-2) might be used to identify 
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bipolar disorder in females. A predictive biomarker panel for BD offers the potential to aid in the 
diagnosis, initiate treatment earlier and ideally alter the course of disease with reduced morbidity and 
functional impairment. 
Keywords 
bipolar, biomarker identification, space decomposition, gradient, high dimensional data 
 
1. Introduction 
Bipolar Disorder (BD) is a mental disorder characterized by periods of elevated mood and periods of 
depression (Anderson et al., 2012; American Psychiatric Association, 2013). During the period of 
mania the patient feels or acts abnormally happy, energetic, or irritable (Anderson et al., 2012). They 
often make poor decisions without considering the consequences. The need for sleep is usually reduced 
(American Psychiatric Association, 2013). The causes are not clearly understood, but both genetic and 
environmental factors play a role (Anderson et al., 2012). Changes in many biomarkers or genes, each 
with a small effect, may contribute to risk of BD. About 3% of people in the US have bipolar disorder 
at some point in their life (Schmitt et al., 2014). Rates appear to be similar in males and females 
(Diflorio & Jones, 2010). The World Economic Forum report estimates the global cost of mental illness 
at nearly $2.5T (two-thirds in indirect costs) in 2010, with a projected increase to over $6T by 2030 
(Bloom et al., 2011).  
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of 
normal biologic or pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Atkinson et al., 2001). Those characteristics can be used to categorize the disease risk in a population 
or as an adjunct to diagnosis. For example: (a) prognostic biomarkers classify cancer patients into 
subgroups with distinct expected risks, but they do not inform the choice of therapy; while (b) 
predictive biomarkers can identify cancer patients, for example, whose tumors are likely to have 
therapeutic sensitivity or resistance based upon marker status (Simon & Altman, 1994; Sargent et al., 
2005). The identification of biomarkers, which often have a weak relationship individually, may help to 
develop new diagnostic tests for early identification and treatment. Successful assay verification and 
biological validation of such biomarkers and selection of high risk populations can be of benefit to both 
patients and society.  
The precise etiology of BD remains uncertain and is most likely multifactorial and complex. BD is 
often misdiagnosed or diagnosed late in the course of the disease, leading to adverse social and medical 
consequences (Houenou et al., 2011). Multiple studies examining neuroimaging, peripheral markers, 
and genetics have provided important insights into the underlying pathophysiologic processes. While 
there is a large body of research examining various factors associated with BD, some of these results 
are inconsistent. Due to the variety in clinical presentations and course of BD, the etiology of BD is 
highly unlikely to be limited to a single risk factor and likely includes interactions of genetic, 
epigenetic, and environmental factors. Occasionally, families may exist in which a single biomarker 
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plays the major role in determining susceptibility, but the majority of BD involves the interaction of 
multiple biomarkers or more complex genetic mechanisms (Craddock & Jones, 1999).  
In other areas of medicine, validated biomarkers now inform clinical decision-making (Frey et al., 
2013). The complexity of the task is compounded by the heterogeneity of BD, which is reflected in the 
broad variety of its clinical presentations, some of which could be a result of different etiopathogenic 
pathways (Washington University, 2014). Many single biomarkers might have a very small effect size 
in statistical models, but together, they may have considerably larger effect, hence, we need to develop 
an approach to identify, measure, and analyze a combination of multiple potential predictors. The 
detection of multiple biomarkers, with small individual statistical effects, requires large sample sizes, a 
large number of measured biomarkers, and appropriate statistical approaches to ensure that valuable 
information is not lost. 
In our earlier work on biomarkers for schizophrenia (Li et al., 2015) it was noted that regression of high 
dimensional data is difficult. When the sample size is small, traditional regression methods, such as the 
Ordinary Least Sqaure (OLS) approach perform poorly (Tibshirani, 1996). When using a high number of 
biomarkers as some predictors are often highly correlated (multicollinearity), and the multiple 
regressions may lead to erratic changes in the effects of individual biomarkers and large standard errors 
of the coefficient estimates in response to small changes in the model. A high degree of multicollinearity 
may also lead to either software failure in matrix inversion or inaccurate results. The result is that the 
selection of biomarkers is difficult and the estimated effect of the predictor variables is expected to be 
biased. If there is a group of variables among which the correlations are very high, then most regression 
approaches, including OLS and Least Absolute Shrinkage and Selection Operator (LASSO) regression 
only select one variable from the group. The ideal biomarker selection method should be able to do two 
things: (1) eliminate the trivial biomarkers, and (2) include whole groups of biomarkers into the model 
once one is selected (Zou & Hastie, 2005). 
Principal Component Analysis (PCA) and Ridge regression (Hastie et al., 2001) are commonly used to 
solve the collinearities and associated bias in traditional regression methods. Principal component 
analysis is also a common method used to reduce the number of predictive variables, but PCA does not 
use information of the dependent variable for the construction of these linear combinations. The first 
principal component is often not the linear combination of the input variables that is most significantly 
associated with the dependent variable of disease state (Johnson & Wichern, 1982; Bair et al., 2006). 
Neither does PCA guarantee that only a few principal components can fit the model well. For the Hald’s 
data (Chatterjee & Hadi, 2012) with four predictors, the 4th eigen vector with the smallest eigen value 
was the only significant predictor. The ridge regression has the same difficulty as OLS when the sample 
size is small. 
We applied a Decomposition-Gradient-Regression (DGR) method with the goal to find a new method 
that works as well as classical regression, when the assumptions are valid, and which works better than 
the classic approach when multicollinerity exists (Li et al., 2015). DGR eliminates the trivial predictors 
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and automatically includes whole groups consisting of highly correlated predictors into the model once 
one predictor among them is selected. In this study, we use the DGR to study bipolar biomarker data to 
identify individual and groups of biomarkers associated with the risk of BD diagnosis. Li et al. has used 
US military data and simulation data with a binary outcome Y and 100 predictors to examine the effects 
of the gradient and the orthogonal scores (Li et al., 2012; Li et al., 2015). The results from both kinds of 
data showed that no score other than the gradient score had a significant effect to distinguish the binary 
outcome. The gradient score consisted of nearly all the information from all biomarkers in the gradient. 
Similar analyses were also performed for bipolar data with similar findings. Therefore only gradients 
scores are used in the reduction process for DGR in this study. The purpose of this study was to select 
biomarkers that are predictive of a diagnosis of BD. 
 
2. Methods 
2.1 Data 
Demographic and clinical data for US military service members who received medical discharges with 
a diagnosis of BD from 1992 to 2006 were obtained from the US Army Physical Disability Agency, the 
Secretary of the Navy Council of Review Boards, and the US Air Force Personnel Center, Physical 
Disability Division (Niebuhr et al., 2011). Those aged 18 and older who were on active duty at the time 
of their bipolar diagnosis, and who had at least one serum sample of 0.5 ml or greater stored in the 
Department of Defense Serum Repository (DoDSR) obtained prior to diagnosis were selected as 
potential study cases. The time of BD onset was estimated as the earliest date of either the first 
hospitalization with psychiatric disorder International Classification of Disease 9th Revision 
(ICD-9-CM) codes (290-319), or the date the medical or physical evaluation board reviews were 
initiated. Control subjects were selected from the active duty US military service population who were 
18 or older, had no inpatient or outpatient mental health diagnoses, and who had at least one serum 
sample of 0.5 ml or greater stored in the DoDSR. All control subjects were matched to their cases on 
sex, race, branch of military service, date of birth (+/-12 months), and date of military enlistment (+/-12 
months). 
The medical and demographic data from 1989 to 2006 were provided in 2007 by the Defense Medical 
Surveillance System, Armed Forces Health Surveillance Branch (AFHSB) (previously named Armed 
Forces Health Surveillance Center) , Silver Spring, MD. Serum specimens from 1988 to 2006 were 
retrieved in 2007 and 2008 from the DoDSR, AFHSB, Silver Spring, MD. However, due to study 
budget limitations, only a subset (n=132) of the bipolar cases with their matched controls was selected 
for serum sample retrieval. Serum specimens were originally collected from service members 
approximately every two years for routine HIV screening, and excess serum was stored at -30°F. Two 
matched (+/-90 days) specimens from controls were selected for each case. The time of specimen 
collection for controls was determined by date of collection of their matched cases. Sera were then 
transferred to the Stanley Neurovirolgy Laboratory, the Johns Hopkins University, School of Medicine, 
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Baltimore, MD, USA for laboratory testing.  
2.2 Statistical Analysis 
To avoid collinearity bias, we first separated the correlated biomarkers into different groups based on 
linear correlations among biomarkers, which we called subspaces. Second we found the gradient 
direction which is the normal vector of a hyperplane in each subspace that best separates the cases and 
controls within the subspace (Li et al., 2012). The gradient score is the linear combination of the 
standardized values of biomarkers used in each subspace. Scores were generated for the gradient and 
their perpendicular vectors in each subspace. The gradient score and the other significant vector scores 
from each subspace were used as factors in the statistical modeling. Third, we eliminated the 
biomarkers with weakest effect backwards by examining the coefficients of the gradient and the effect 
on the gradient score model in each subspace. Then the regression model was utilized on the gradient 
scores to select biomarkers.  
Given that multiple serum samples were collected for each subject from different times prior to 
diagnosis, the Generalized Estimating Equation (GEE) was used to estimate the unknown parameters 
(Liang & Zeger, 1986). The odds ratios and 95% confidence intervals or p-values were reported using 
Bonferroni correction. The degrees of freedom of the Wald chi-square value of the gradient score was 
adjusted by the number of biomarkers used in the gradient vector. The coefficient of a biomarker in the 
gradient vector describes its contribution to distinguish bipolar cases from the controls. If the 
coefficient of a given biomarker is near zero, it implies that it has no effect on bipolar diagnosis 
identification, and can then be eliminated from the gradient without loss of information by a backwards 
elimination process. 
Two approaches for the number of biomarkers to be selected were used. The first approach used surface 
figures constructed by sensitivity estimates generated with regression modeling and the numbers of 
biomarkers used in subspaces A and B by using simulation. For each simulation, two-thirds of subjects 
were randomly assigned to the training dataset and used to fit to the model, and the remaining one-third 
to the testing set were used to verify the model. The second approach used the Akaike Information 
Criterion (AIC) AIC=2p-2Log L, which is a measure of the quality of fit of a statistical model for a 
given set of data, where p is the number of parameters in the regression. For longitudinal GEE 
regression, the Quasi-Likelihood Information Criterion (QIC), which uses the quasi likelihood to 
replace the likelihood in AIC, is commonly used (Pan, 2001). When we use the gradient score in the 
model because only partial information of the individual biomarker is used, we modify the AIC as 
Modified Akaike Information Criterion MAIC=k-2Log L, where k is the number of biomarkers used in 
the gradient score rather than AIC=2-2LogL for the gradient only. When logistic regression was 
performed with gradient scores, the individual biomarker effect was estimated from the gradient score 
effect multiplying by the percent contribution of that biomarker to the gradient, which is the square of 
the coefficient in the unit gradient vector. 
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3. Results 
The 64 biomarkers and antibodies to infectious agents used in this study are listed in (Table 1). Due to 
case-control match, only the case subject distribution and sample distribution are needed to be shown 
(Table 2). About 14 (%) of the 132 bipolar patients were females. The literature has shown 
inconsistency of biomarker effects (Schwarz et al., 2010; Pruijm et al., 2013) based on sex and 
therefore, we focused the analyses on males. A similar decomposition gradient and reduction analyes 
for females is reported for simple comparison and discussion. 
3.1 Biomarker Selection for Males 
Among the 64 biomarkers and antibody agents, one pair (Myeloperoxidase (MPO) and Neutrophil 
Gelatinase-Associated Lipocalin (NGAL)) was highly correlated (Pearson correlation coefficient of 
0.81), and three pairs were also correlated (Pearson correlation coefficient over 0.7) Neuronal Cell 
Adhesion Molecule (Nr-CAM) and Prolactin (PRL), MPO and EN-RAGE, Apolipoprotein A-I (ApoA-I) 
and Apolipoprotein A-II (ApoA-II). An additional 37 pairs of biomarkers had an absolute value of 
Pearson correlation coefficients over 0.40. First using Pearson correlation coefficients of ±0.4 as the 
threshold, the 64 biomarkers were separated into three groups: subspaces A, B and C. Any pairs of 
biomarkers with an absolute value of Pearson correlation coefficients over 0.40 were in different 
subspaces. There were seven biomarkers in subspace C, all of which were eliminated because their 
gradient had no contribution to identify bipolar cases, and the logistic regression with the seven 
biomarkes fitted the data poorly (the difference of G2=-2LOG L, which is Chi square distributed, is 
about 10 by adding the seven biomarkers). 
The effect of gradient C and the effects of individual biomarkers were approximated as zero. The 
gradient scores were highly significant in both subspaces A and B by using Bonferroni correction 
(adjusted p<0.05/kA and p<0.05/kB respectively, where kA and kB were the number of biomarkers used in 
the gradients in subspaces A and B). Using the backward elimination approach for the data on males, 
the biomarkers with a coefficient nearest to zero in the gradient vector were eliminated one by one. The 
average sensitivity for BD status among 100 simulations was used to make the surface graphs by the 
number of biomarker used in subspaces A and B (Figures 1 and 2 respectively).  
For subspace A, the sensitivity increased with the number of biomarkers up to peak for the training set 
of 10 biomarkers and then decreased. A similar pattern was observed for the testing set. Considering 
sensitivities for both training and testing sets, we should select between 8-10 biomarkers from the 
subspace A. The effect of the number used in subspace B was limited and three biomarkers were 
selected. Further increases in the number of biomarkers did not yield any improvement in sensitivity 
for the training set, but caused a lowering of the sensitivity for testing set. The MAIC curve by the 
number of biomarkers in subspace A, is shown in (Figure 3), which was minimized at k=9. The number 
of biomarkers in subspace B (Figure 4) was minimized at k=3. The two approaches provided nearly the 
same results for nine biomarkers from subspace A and three biomarkers from subspace B, and these 
biomarkers were selected for further analyses. 
www.scholink.org/ojs/index.php/rhs                   Research in Health Science                         Vol. 2, No. 3, 2017 
268 
Published by SCHOLINK INC. 
3.2 The Effects of Selected Biomarkers among Males 
To test the effect of selected biomarkers, the selected gradient models with (5, 3), (9, 3), and (9, 5) 
biomarkers in subspaces A and B, respectively, were used. The first number is the biomarkers used to 
generate the gradient score in the subspace A, and the second number is the biomarkers used to generate 
the gradient score in subspace B. Both three and five biomarkers in subspace B were used to check the 
robustness of the model. The gradient scores are the predictor in the logistic model. Wald Chi-square, a 
conservative approach, was used to test significance (Agresti, 2012). The adjusted Chi-squared test 
p-value for gradient score was based on the number of biomarkers used. The results (Table 3) were as 
follows: 
1. The effects of both gradient scores are significant. 
2. The size of the OR of individual gradient in either subspace increased minimally as the number of 
biomarkers used increased. For example, the OR of gradient A was 2.16 in Model (5, 3) and 2.60 in 
Model (9, 3) suggesting that a minor contribution associated with adding four additional biomarkers. 
3. The effect of the gradient score from subspace A changed little when the number of biomarkers 
used in the subspace B changed. For example the OR of gradient A was 2.60 in Model (9, 3) with three 
biomarkers used in B and 2.64 in Model (9, 5) with five biomarkers used in B. Similar performance was 
also observed for the gradient of subspace B. The OR of Gradient B was 1.70 in Model (5, 3) and 1.75 in 
Model (9, 3), inferring that the gradient scores from different subspaces were almost independent. No 
multicollienarity was found when performing the regression with gradient scores. 
Table 4, lists the standard coefficients of the individual biomarker in the gradient scores. The 
percentage of contribution on the gradient score effect on BD is the square of the coefficients. The third 
column is the odds ratio for increasing one standard deviation of the individual biomarkers along the 
gradient direction. It also shows the individual biomarker effect on bipolar identification according to 
their contribution to the gradients in the selected model (9, 3) vs. model (5, 3). The model (9, 3), resulted 
in three biomarkers in the Subspace A with significant effects: Trefoil Factor 3 (TFF3) with OR=1.14, 
Gliadin with OR=1.34 and Prolactin (PRL) with OR=0.83. Two biomarkers in the Subspace B were 
significant: Apolipoprotein A-II (Apo A-II) with OR=1.20 and Immunoglobulin A (IgA) with OR=0.81. 
When we applied model (5, 3), the significance and the ORs of the above biomarkers were minimally 
changed. This observation supports the conclusion that the estimations of the individual biomarkers are 
reliable. 
3.3 The Sensitivity of Biomarker Selection among Males 
In order to check the sensitivity of the biomarker selection, 100 males were randomly selected from the 
118 males with bipolar disorder, and 11 females were randomly selected from 14 females with bipolar 
disorder. The selection was repeated 100 times to derive 100 data sets with their matched controls. Then 
the backward gradient elimination process was performed for each sample. The biomarkers with the 
highest selection frequency and the average coefficents in the gradient vector are listed in Table 5 for the 
Subspaces (9, 3). For the data on males, if nine biomarkers were selected, Prolactin (PRL), Trefoil Factor 
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3 (TFF3), gliadin and vaccinia were selected over 98 times. Comparing the results in Tables 4 and 5 for 
males, the selected biomarkers are the same and the coeffients are consistent. The top three significant 
biomarkers were selected over 99% in subspace A, and the two significant biomarkers in subspace B 
were selected over 91%. The standard deviations (std) of the coefficients in the gradient were less than 
one fifth to one tenth of the coefficients for males. 
3.4 Biomarker Selection among Females 
The number of female cases was limited to 14 which was unreliable for performing the regression 
analysis, hence only Decomposition-Gradient-Reduction was used. It is unreliable to make a solid 
conclusion about the biomarker effect on BD based on the small sample size. Among the 100 
simulations, Table 5 shows that the top three biomarkers in subspace A and for the top two biomarkers in 
Subspace B were selected over 60%. The standard deviation was less than one third of the coefficient. 
Macrophage-Derived Chemokine (MDC), Alpha-1-Antitrypsin (AAT) and gliadin in subspace A and 
Beta-2-Microglobulin (B2M) and monocyte chemotactic protein 2 (MCP-2) were selected. Using DGR, 
as we did for males, all of these biomarkers were significantly associated with identifying BD cases. 
 
Table 1. List of Biomarkers for Bipolar after Decomposition by Subspaces of Observed Linear 
Correlation 
Subspace A Peptidey y (PYY) 
Alpha-1-Antitrypsin (AAT) Prolactin (PRL) 
Apolipoprotein A-I (Apoa-I) Prostatic Acidphosphatase (PAP) 
Apolipoprotein b (Apob) Sortilin 
Betacellulin (BTC) Testosterone_Total 
Brain-Derived Neurotrophic Factor (BDNF) Thyroid-Stimulating Hormone (TSH) 
Cancer Antigen125 (CA-125) TNF-Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL-R3) 
Carcinoembryonic Antigen (CEA) Trefoil Factor 3 (TFF3) 
Casein Tumor Necrosis Factor Receptor 2 (Tnfr2) 
Cd5 (Cd5l) Vaccinia 
Cytomegalovirus (CMV) 
 
Complement c3 (C3) Subspace B 
Connective Tissue Growth Factor (CTGF) Alpha-1-Microglobulin (A1Micro) 
Cortisol (Cortisol) Apolipoprotein A-II (Apo A-II) 
Epidermal Growth Factor Receptor (EGFR) Beta-2-Microglobulin (B2M) 
Ferritin (FRTN) Calbindin 
Fetuin-A Immunoglobulin A (IGA) 
Follicle-Stimulating Hormone (FSH) Kidney Injury Molecule-1 (KIM-1) 
Gliadin Monocyte Chemotactic Protein 2 (MCP-2) 
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Haptoglobin Neuronal Cell Adhesion Molecule (Nr-CAM) 
Herpes simplex virus (HSV)-1 Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
Herpes simplex virus (HSV)-2 Serotransferrin (Transferrin) 
Immunoglobulin M (IGM) Serum Amyloid P-component (SAP) 
Intercellular Adhesion Molecule 1 (ICAM-1) Thrombospondin-1 
Interleukin-10 (IL-10) Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) 
Interleukin-6 Receptor (IL-6r) Subspace C 
Interleukin-7 (IL-7) Apolipoprotein C-I (Apo C-I) 
Leptin Apolipoprotein H (Apo H) 
Macrophage-Derived Chemokine (MDC) Cystatin-C 
Macrophage Inflammatory Protein-1 Alpha 
(MIP-1alpha) 
EN-RAGE 
Macrophage Migration Inhibitory Factor (MIF) Luteinizing Hormone (LH) 
Matrix Metalloproteinase-2 (MMP-2) Vascular Endothelial Growth Factor (VEGF) 
Measles Vitronectin 
Myeloperoxidase (MPO) 
 
 
Table 2. Distribution of Bipolar Disorder Subjects and Serum Specimens by Sex, Race, and Age
a
 
Factor Level 
Bipolar Disorder Subjects Serum Specimens 
count % count % 
Sex 
Female 14 10.6 28 10.6 
Male 118 89.4 236 89.4 
Race 
Other 9 6.8 18 6.8 
White 123 93. 2 246 93. 2 
Age (yrs) 
<25 60 45.5 120 45.5 
≥25 72 54.5 144 54.5 
a Case and control are matched, hence only distribution of cases is listed. 
 
Table 3. The Odds Ratio Per One Standard Deviation Increasing of Gradient Score for Bipolar 
Disorder Diagnosis among Several Selected Number of Biomarkers in Subspace A and B 
Model 
(A, B)a 
Gradient score 
by subspace 
OR 95% CI  
Unadjusted 
P value  
Significance 
with Bonferroni 
correction 
Adjusted Wald 
Chi-Square 
P valueb 
(5,3) 
A 2.16 1.58 2.93 1.0E-06 Yes 2.E-04 
B 1.70 1.28 2.26 2.5E-04 Yes 4.E-03 
(9,3) A 2.60 1.85 3.66 3.6E-08 Yes 0.03 
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B 1.75 1.31 2.35 1.6E-04 Yes 4.E-04 
(9,5) 
A 2.64 1.87 3.74 7.9E-11 Yes 4.E-04 
B 1.89 1.40 2.55 6.0E-03 Yes 4.E-03 
a (A, B), A is the number of biomarkers used from Subspace A and B is the number of biomarkers used 
from Subspace B. 
b Adjusted by Bonferroni correction. 
 
Table 4. The Effect of Individual Biomarker among Males on Bipolar Disorder Diagnosis  
Model (numbers of biomarkers used) (A = 9 and B = 3) (A = 5, B = 3) 
Subspace Biomarkers 
Gradient Score 
Coefficient 
Percentage 
contribution 
Odds 
Ratioa 
Gradient Score 
Coefficient 
Percentage 
contribution 
Odds 
Ratioa 
A Trefoil Factor 3 (TFF3) 0.37 0.14 1.14* 0.43 0.18 1.15* 
CMV antibody -0.26 0.07 0.94 -0.29 0.08 0.94 
Gliadin 0.55 0.31 1.34* 0.6 0.36 1.31* 
Prolactin (PRL) -0.44 0.2 0.83* -0.49 0.24 0.76* 
Vaccinia antibody -0.35 0.12 0.89 -0.36 0.13 0.91 
Testosterone Total -0.19 0.03 0.97 
  
  
Haptoglobin 0.19 0.04 1.03 
  
  
Leptin 0.2 0.04 1.04 
  
  
HSV-1 antibody 0.25 0.06 1.06 
  
  
B Apolipoprotein A-II (ApoA-II) 0.58 0.34 1.20* 0.58 0.34 1.20* 
Immunoglobulin A (IGA) -0.63 0.39 0.81* -0.63 0.39 0.81* 
Neuronal Cell Adhesion Molecule 
(Nr-CAM) 
-0.52 0.27 0.87 -0.52 0.27 0.87 
* Significant at level<0.05. 
 
Table 5. Percentage of Biomarker Selection among 100 Model Simulations
a
 
Subspace 
Male Female 
Biomarkers Percentage Coefficient Std Biomarkers Percentage Coefficient Std 
A 
Prolactin (PRL) 100 -0.44 0.05 
Macrophage-Derived 
Chemokine (MDC) 
79 0.4 0.1 
Trefoil Factor3 (TFF3) 99 0.37 0.06 
Alpha-1-Antitrypsin 
(AAT) 
70 0.43 0.11 
Gliadin 99 0.53 0.05 Gliadin 57 -0.36 0.1 
Vaccinia Antibody 98 -0.33 0.06 
Macrophage Migration 
Inhibitory Factor (MIF) 
51 -0.31 0.06 
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CMV antibody 78 -0.26 0.04 Measles antibody 49 0.33 0.09 
HSV-1 antibody 75 0.25 0.04 
Carcinoembryonic 
Antigen (CEA) 
46 -0.3 0.09 
Haptoglobin 51 0.24 0.05 Casein Antibody 39 0.34 0.12 
Leptin 43 0.22 0.04 Complement C3 27 -0.31 0.12 
Follicle-Stimulating 
Hormone (FSH) 
40 -0.21 0.04 Cytomegalovirus CMV 24 -0.15 0.21 
B Apolipoprotein A-II (Apo 
A-II) 
98 0.59 0.06 
Beta-2-Microglobulin 
(B2M) 
91 -0.63 0.13 
Immunoglobulin A (IGA) 91 -0.61 0.08 
Monocyte Chemotactic 
Protein 2 (MCP-2) 
61 0.58 0.1 
Neuronal Cell Adhesion 
Molecule (Nr-CAM) 
75 -0.53 0.08 
Immunoglobulin A 
(IGA) 
45 0.46 0.11 
a 100 simulation data set were generated by jackknife approach. 
 
 
Figure 1. Average Sensitivity to Predict Bipolar Disorder Diagnosis of Training Group by Number 
of Biomarkers in Subspaces A and B 
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Figure 2. Average Sensitivity to Predict Bipolar Disorder Diagnosis of Testing Group by Number 
of Biomarkers in Subspaces A and B 
 
 
Figure 3. The Modified Akaike Information Criterion (MAIC) Curve by the Number of 
Biomarkets Used in Subspace A 
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Figure 4. The Modified Akaike Information Criterion (MAIC) Curve by the Number of 
Biomarkets Used in Subspace B 
 
4. Discussion 
In the military sample subject dataset and the 64 biomarkers and infectious agents antibodies examined, 
TFF3, Gliadin, PRL, ApoA-II and IgA showed a significant relationship to BD diagnostic status in 
males and MDC, AAT, Gliadin, B2M and MCP-2 are suggested to identify BD in females. There are 
similarities between this study and other research. MDC was found previously to be associated with a 
diagnosis of schizophrenia (Pruijm et al., 2013). AAT was found to be increased in patients with 
anxiety disorders and bipolar I and bipolar II disorders (Sachar et al., 1973; Levin et al., 2010). MIF 
has been found to be increased with anxiety and depression-like behaviors and with impaired 
hippocampus-dependent memory (Conboy et al., 2011; Schmechel et al., 2012). An association 
between BD and B2M has been observed (Musil et al., 2011). Patients with anxiety, depression and 
schizophrenia have also been found to have high levels of B2M (Rybokowski et al., 2013).  
Many studies have found a relationship between cancer and TFF3, but there are no prior studies assessing 
the relationship between BD and TFF3 directly. Cerebral TFF3 has been reported to be involved in 
several processes such as fear, depression, learning and object recognition, and opiate addiction 
(Bernstein et al., 2015). This study demonstrated that an increase of one standard deviation of TFF3 
results in a 14% increased risk of BD. Several studies have demonstrated that PRL was increased among 
females with BD (Sachar et al., 1973; Sher et al., 2003; Schmidt et al., 2013). Paing et al. noted that 
hyperprolactinemia may be caused by hypothyroidism, pituitary disorders, atypical antipsychotics, or 
other conditions and medications and has numerous physiologic manifestations, including amenorrhea 
and infertility (Paing et al., 2011).  
We found that prolactin is inversely related (0.83) with BD in males which is the opposite effect we 
found in a schizophrenia study (Ramsey et al., 2013). Further study of the gender effect of PRL on BD. 
Few studies regarding the relationship between Apo II and BD were found in the literature. There is 
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considerable similarity across the apo family and previous studies on apo AI have noted that, in BD 
patients, the Apo I level is increased which is consistent with prior findings by Herberth (Herberth et al., 
2011; Sussulini et al., 2011; Pruijm, et al., 2013). Furthermore, we found that Apo A II was a significant 
risk factor (OR=1.2 per one standard deviation increase) for BD.  
We report a novel three step biomarker selection process to identify bipolar cases. The first step 
involved decomposition of the sample space by examining the dependency of 64 biomarkers, separated 
into three subspaces to avoid collinearity. The second step involved biomarker selection using the 
gradient in each subspace parameter in the regression to select important biomarkers without losing 
information. The third step identified the effects of biomarkers in combination and individually. 
Compared with other approaches, such as Classification and Regression Trees and LASSO, the 
advantage of DGR is that the magnitude and direction of the individual biomarker effects can be 
estimated (Li et al., 2015) with the association expressed as an odds ratio which is more easily 
understood as an estimate of risk.  
We used a novel approach to identify a potential panel of biomarkers that are strongly associated (OR 
over 2) with the diagnosis of BD. The reliable identification of biomarkers from high dimensional data 
is a key discipline in modern pharmaceutical and biotechnical research. Once these biomarkers have 
been found and validated they can be used to identify patients at either high or low risk of BD 
diagnosis potentially earlier than relying on clinical diagnostic criteria. Selection of predictive 
biomarkers by DGR has a number of epidemiological and statistical analytic advantages: 1) the risk of 
over-fitting is reduced, which improves the predictive accuracy; 2) the number of parameters is reduced, 
which decreases the sample collection costs; 3) models based on fewer factors are often easier to 
interpret; and 4) both joint and individual biomarker effect can be estimated. 
This hypothesis-generating study must be validated in other populations, as the methods of specimen 
collection, storage and testing of serum specimens may vary, the underlying populations of cases and 
controls may differ, and some significant biomarkers in our study might have been selected by chance. 
In addition, the biological mechanisms of the biomarkers in the pathophysiology of BD should be 
studied to avoid selection bias in the final predictive model. A predictive biomarker panel for BD offers 
the potential for earlier diagnosis and initiation of treatment for BD with the long term goal of reduced 
morbidity and functional impairment in BD patients. 
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